Аннотация
Саркопеническое ожирение (СО) представляет собой особый фенотип ожирения, характеризующийся сочетанием избыточного накопления жировой ткани со снижением массы и функции скелетных мышц. У мужчин развитие данного состояния тесно связано с возрастным снижением уровня тестостерона, митохондриальной дисфункцией, хроническим воспалением низкой интенсивности и инсулинорезистентностью. СО сопровождается нарушением метаболического гомеостаза, повышением риска развития сахарного диабета 2-го типа, сердечно-сосудистых заболеваний, остеосаркопенического синдрома и снижением качества жизни. В обзоре обсуждаются современные методы оценки состава тела, силовых и функциональных показателей, а также терапевтические подходы, включающие дозированные физические нагрузки, оптимизацию белкового питания, коррекцию дефицита витамина D и андрогенов. СО у мужчин рассматривается как самостоятельный мультифакторный эндокринно-метаболический синдром, требующий ранней диагностики и междисциплинарного подхода к ведению пациентов.
Ключевые слова: саркопеническое ожирение, андрогенный дефицит, митохондриальная дисфункция, инсулинорезистентность, микробиота кишечника, витамин D, миокины, воспаление, метаболический синдром.
Ключевые слова: саркопеническое ожирение, андрогенный дефицит, митохондриальная дисфункция, инсулинорезистентность, микробиота кишечника, витамин D, миокины, воспаление, метаболический синдром.
Об авторе
Ф.Х. Дзгоева, В.В. Демидова
ФГБУ «Национальный медицинский исследовательский центр эндокринологии им. акад. И.И. Дедова» Минздрава России, Москва, Россия
fatima.dzgoeva@gmail.com
ФГБУ «Национальный медицинский исследовательский центр эндокринологии им. акад. И.И. Дедова» Минздрава России, Москва, Россия
fatima.dzgoeva@gmail.com
Список литературы
1. Бернс С.А., Шептулина А.Ф., Мамутова Э.М. и др. Саркопеническое ожирение: эпидемиология, патогенез и особенности диагностики. Кардиоваскулярная терапия и профилактика. 2023;22(6):3576. DOI: 10.15829/1728-8800-2023-3576. EDN: OWOAYO
Berns S.A., Sheptulina A.F., Mamutova E.M. et al. Sarcopenic obesity: epidemiology, pathogenesis and diagnostic criteria. Cardiovascular Therapy and Prevention 2023;22(6):3576. DOI: 10.15829/1728-8800-2023-3576. EDN: OWOAYO (in Russian).
2. Wagenaar CA, Dekker LH, Navis GJ. Prevalence of sarcopenic obesity and overweight in general population: Lifelines cohort. Clin Nutr 2021;40(6):4422-9. DOI: 10.1016/j.clnu.2021.01.005
3. Scott D, Blyth F, Naganathan V et al. Sarcopenia prevalence and functional outcomes in obese older men: comparing EWGSOP2 vs ESPEN-EASO definitions. Clin Nutr 2023;42(9):1610-8. DOI: 10.1016/j.clnu.2023.07.014
4. Tian S, Xu Y. Association of sarcopenic obesity with risk of all-cause mortality: meta-analysis. Geriatr Gerontol Int 2016;16(2):155-66. DOI: 10.1111/ggi.12579
5. Wang M, Tan Y, Shi Y et al. Diabetes and sarcopenic obesity: pathogenesis, diagnosis, and treatments. Front Endocrinol 2020;11:568. DOI: 10.3389/fendo.2020.00568
6. Larsson L, Degens H, Li M et al. Sarcopenia: aging-related loss of muscle mass and function. Physiol Rev 2019;99:427-511.
7. Gheller BJ, Riddle ES, Lem MR, Thalacker-Mercer AE. Age-related skeletal muscle metabolism: sex differences. Annu Rev Nutr 2016;36:129-56. DOI: 10.1146/annurev-nutr-071715-050901
8. Wall BT, Gorissen SH, Pennings B et al. Aging is accompanied by a blunted muscle protein synthetic response to protein ingestion. PLoS One 2015;10:e0140903.
9. Deschenes MR, Oh J, Tufts H. The role of the neuromuscular junction in sarcopenia. In: Sakuma K, ed. Sarcopenia. Amsterdam; 2021. P. 59-80.
10. Feldman HA, Longcope C, Derby CA et al. Age trends in serum testosterone: Massachusetts Male Aging Study. J Clin Endocrinol Metab 2002;87(2):589-98. DOI: 10.1210/jcem.87.2.8201
11. Lauretani F, Russo CR, Bandinelli S et al. Age-associated changes in skeletal muscles and mobility: operational diagnosis of sarcopenia. J Appl Physiol 2003;95:1851-60.
12. Mesinovic J, Zengin A, De Courten B, et al. Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship. Diabetes Metab Syndr Obes 2019;12:1057-72.
13. Xia MF, Chen LY, Wu L et al. Sarcopenia, sarcopenic overweight/obesity and risk of cardiovascular disease. Clin Nutr 2021;40:571-80.
14. Kang DO, Park SY, Choi BG et al. Prognostic impact of low skeletal muscle mass on major adverse cardiovascular events in coronary artery disease. J Clin Med 2019;8:712.
15. Hong SH, Choi KM. Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences. Int J Mol Sci 2020;21:494.
16. Su J, Ekman C, Oskolkov N et al. Atlas of gene expression in human skeletal muscle reveals molecular changes associated with aging. Skeletal Muscle 2015;5:35. DOI: 10.1186/s13395-015-0059-1
17. Salehzadeh F, Rune A, Osler M, Al-Khalili L. Testosterone or 17β-estradiol exposure reveals sex-specific effects on glucose and lipid metabolism in human myotubes. J Endocrinol 2011;210(2):219-29. DOI: 10.1530/JOE-10-0497
18. Frederiksen L, Højlund K, Hougaard DM et al. Testosterone therapy increased muscle mass and lipid oxidation in aging men. Age (Dordr) 2012;34:145-56. DOI: 10.1007/s11357-011-9213-9
19. Kalyani RR, Kim C, Ferrucci L et al. Sex differences in fasting and postchallenge glucose levels associated with grip strength in older adults: Rancho Bernardo Study. BMJ Open Diabetes Res Care 2015;3:e000086.
20. Aragon AA, Tipton KD, Schoenfeld BJ. Age-related muscle anabolic resistance: inevitable or preventable? Nutr Rev 2023;81(4):441-54. DOI: 10.1093/nutrit/nuac062
21. Chen LK, Arai H, Assantachai P et al. Nutrition and muscle health: Asian Working Group consensus. J Cachexia Sarcopenia Muscle 2022;13:1653-72.
22. Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, CVD and frailty. Nat Rev Cardiol 2018;15:505-22.
23. Lang CH, Frost RA, Vary TC. Regulation of muscle protein synthesis during sepsis and inflammation. Am J Physiol Endocrinol Metab 2007;293:E453-E459.
24. Barberi L, Scicchitano BM, De Rossi M et al. Age-dependent alteration in muscle regeneration: the critical role of tissue niche. Biogerontology 2013;14:273-92.
25. Суплотова Л.А., Авдеева В.А., Рожинская Л.Я. К вопросу о патогенетических механизмах влияния ожирения на уровень витамина D. Ожирение и метаболизм. 2021;18(2):169-74. DOI: 10.14341/omet12578
Suplotova L.A., Avdeeva V.A., Rozhinskaya L.Ya. To the question of the pathogenetic mechanisms of the influence of obesity on the level of vitamin D. Obesity and metabolism. 2021;18(2):169-74. DOI: 10.14341/omet12578 (in Russian).
26. Мисникова И.В., Ковалева Ю.А., Климина Н.А. Саркопеническое ожирение. РМЖ. 2017;(1):24-9.
Misnikova I.V., Kovaleva Yu.A., Klimina N.A. Sarcopenic obesity. RMJ. 2017;(1):24-9.
27. Granic A, Hill TR, Davies K et al. Vitamin D status, muscle strength and physical performance decline in very old adults: a prospective study. Nutrients 2017;9(4):379.
28. Remelli F, Vitali A, Zurlo A, Volpato S. Vitamin D deficiency and sarcopenia in older persons. Nutrients 2019;11(12):2861. DOI: 10.3390/nu11122861
29. Spira D, Buchmann N, König M et al. Sex-specific differences in vitamin D association with low lean mass and frailty: Berlin Aging Study II. Nutrition 2019;62:1-6. DOI: 10.1016/j.nut.2018.11.020
30. Girgis CM, Clifton-Bligh RJ, Turner N et al. Effects of vitamin D on muscle: falls, strength, insulin sensitivity. Clin Endocrinol (Oxf) 2014;80(2):169-81. DOI: 10.1111/cen.12368
31. Bass JJ, Kazi AA, Deane CS et al. Mechanisms of skeletal muscle atrophy after transient knockdown of the vitamin D receptor in vivo. J Physiol 2021;599(3):963-79. DOI: 10.1113/JP280652
32. Kim TN, Park MS, Lim KI et al. Relationships between sarcopenic obesity, insulin resistance, inflammation, and vitamin D status: the Korean Sarcopenic Obesity Study. Clin Endocrinol (Oxf) 2013;78(4):525-32.
33. Creely SJ, McTernan PG, Kusminski CM et al. LPS activates innate immune response in adipose tissue in obesity and T2D. Am J Physiol Endocrinol Metab 2007;292:E740-E747. DOI: 10.1152/ajpendo.00302.2006
34. Prokopidis K, Cervo MM, Gandham A, Scott D. Impact of protein intake in older adults with sarcopenia and obesity: a gut microbiota perspective. Nutrients 2020;12(8):2285. DOI: 10.3390/nu12082285
35. House LM, Morris RT, Barnes TM et al. Tissue inflammation and nitric oxide-mediated alterations in cardiovascular function determine endotoxin-induced insulin resistance. Cardiovasc Diabetol 2015;14:56. DOI: 10.1186/s12933-015-0223-2
36. Lustgarten MS, Price LL, Chale A, Fielding RA. Metabolites related to gut bacteria, PPAR-α activation, and insulin sensitivity associated with function in older adults. Aging Cell 2014;13:918-25. DOI: 10.1111/acel.12251
37. Grosicki GJ, Fielding RA, Lustgarten MS. Gut microbiota contribute to age-related changes in skeletal muscle size, composition, and function: biological basis for a gut-muscle axis. Calcif Tissue Int 2018;102:433-42. DOI: 10.1007/s00223-017-0345-5
38. Fetissov SO. Gut microbiota in appetite control: from bacterial growth to feeding behaviour. Nat Rev Endocrinol 2017;13:11-25.
39. Schmidt TSB, Raes J, Bork P. The human gut microbiome: from association to modulation. Cell 2018;172:1198-215. DOI: 10.1016/j.cell.2018.02.044
40. Buechler C, Wanninger J, Neumeier M. Adiponectin in obesity-related liver diseases. World J Gastroenterol 2011;17:2801-11.
41. Merli M, Lattanzi B, Aprile F. Sarcopenic obesity in fatty liver. Curr Opin Clin Nutr Metab Care 2019;22:185-90. DOI: 10.1097/MCO.0000000000000558
42. Henningsen J, Rigbolt KTG, Blagoev B et al. Dynamics of the skeletal muscle secretome during myoblast differentiation. Mol Cell Proteom 2010;9:2482-96. DOI: 10.1074/mcp.M110.002113
43. Bonala S, McFarlane C, Ang J et al. Retraction: Pid1 induces insulin resistance in skeletal muscle during obesity. Mol Endocrinol 2013;27:1518-35. DOI: 10.1210/me.2013-1048
44. Hsu KJ, Liao CD, Tsai MW, Chen CN. Effects of exercise and nutritional intervention on body composition, metabolic health, and physical performance in adults with sarcopenic obesity: a meta-analysis. Nutrients 2019;11(9):2163. DOI: 10.3390/nu11092163
45. Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol 2018;14:513-37.
46. Курмаев Д.П., Булгакова С.В., Тренева Е.В. Саркопеническое ожирение – актуальная проблема современной гериатрии. Российский журнал гериатрической медицины. 2022;4(12):228-35. DOI: 10.37586/2686- 8636-4-2022-228-235
Kurmaev D.P., Bulgakova S.V., Treneva E.V. Sarcopenic obesity – a current problem of modern geriatrics. Russian Journal of Geriatric Medicine. 2022;4(12):228-35. DOI: 10.37586/2686- 8636-4-2022-228-235 (in Russian).
47. Villareal D, Chode S, Parimi N et al. Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med 2011;364:1218-29. DOI: 10.1056/NEJMoa1008234
48. Weinheimer EM, Sands LP, Campbell WW. Effects of energy restriction and exercise on fat-free mass in older adults: implications for sarcopenic obesity. Nutr Rev 2010;68:375-88. DOI: 10.1111/j.1753-4887.2010.00298.x
49. Trouwborst I, Verreijen A, Memelink R et al. Exercise and nutrition strategies to counteract sarcopenic obesity. Nutrients 2018;10(5):605. DOI: 10.3390/nu10050605
50. Muscariello E, Nasti G, Siervo M et al. Dietary protein intake in sarcopenic obese older women. Clin Interv Aging 2016;11:133-40. DOI: 10.2147/CIA.S96017
51. Camajani E, Feraco A, Proietti S et al. Corrigendum: VLCKD plus interval training in sarcopenic obesity. Front Nutr 2022;9:1076667. DOI: 10.3389/fnut.2022.1076667
52. Pennings B, Boirie Y, Senden JM et al. Whey protein stimulates postprandial muscle accretion more effectively than casein. Am J Clin Nutr 2011;93:997-1005. DOI: 10.3945/ajcn.110.008102
53. Hector AJ, Marcotte GR, Churchward-Venne TA et al. Whey protein supplementation preserves postprandial myofibrillar protein synthesis during short-term energy restriction in overweight and obese adults. J Nutr 2015;145:246-52. DOI: 10.3945/jn.114.200832
54. Camajani E, Persichetti A, Watanabe M et al. Whey protein, L-leucine and vitamin D to preserve lean mass in sarcopenic obese women. Nutrients 2022;14(9):1884. DOI: 10.3390/nu14091884
55. Cereda E, Pisati R, Rondanelli M, Caccialanza R. Whey/leucine/vitamin D ONS for sarcopenia. Nutrients 2022;14(7):1524. DOI: 10.3390/nu14071524
56. Arnal MA, Mosoni L, Boirie Y et al. Protein pulse feeding improves protein retention in elderly women. Am J Clin Nutr 1999;69:1202-8. DOI: 10.1093/ajcn/69.6.1202
57. Farsijani S, Morais JA, Payette H et al. Mealtime protein distribution and lean mass loss in NuAge. Am J Clin Nutr 2016;104:694-703. DOI: 10.3945/ajcn.116.130716
58. Sakuma K, Hamada K, Yamaguchi A, Aoi W. Current nutritional and pharmacological approaches for attenuating sarcopenia. Cells 2023;12(19):2422. DOI: 10.3390/cells12192422
59. Bhasin S, Calof OM, Storer TW et al. Testosterone and SARMs as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab 2006;2(3):146-59. DOI: 10.1038/ncpendmet0120
60. Dalton JT, Barnette KG, Bohl CE et al. Enobosarm improves lean body mass and function: phase II trial. J Cachexia Sarcopenia Muscle 2011;2:153-61.
61. Supasyndh O, Satirapoj B, Aramwit P et al. Effect of oral anabolic steroid on muscle strength and growth in hemodialysis patients. Clin J Am Soc Nephrol 2013;8:271-9.
62. Woodhouse L, Gandhi R, Warden SJ et al. Myostatin antibody LY2495655 in hip arthroplasty patients: randomized phase 2 study. J Frailty Aging 2016;5:62-70.
63. Becker C, Lord SR, Studenski SA et al. Myostatin antibody (LY2495655) in older weak fallers: a randomized phase 2 trial. Lancet Diabetes Endocrinol 2015;3:948-57.
64. Loffredo FS, Steinhauser ML, Jay SM et al. Growth differentiation factor 11 reverses age-related cardiac hypertrophy. Cell 2013;153:828-39.
65. Sinha M, Jang YC, Oh J et al. Restoring systemic GDF11 levels reverses age-related dysfunction in skeletal muscle. Science 2014;344:649-52.
66. Mafi F, Biglari S, Ghardashi Afousi A, Gaeini AA. Resistance training and epicatechin improve strength, follistatin and myostatin in sarcopenic older adults. J Aging Phys Act 2019;27:384-91.
67. Chang YC, Chen YT, Liu HW et al. Oligonol alleviates sarcopenia via protein turnover and mitochondrial quality pathways. Mol Nutr Food Res 2019;63:e1801102.
68. Mukai R, Nakao R, Yamamoto H et al. Quercetin prevents disuse muscle atrophy by attenuating ubiquitin ligases in mice. J Nat Prod 2010;73:1708-10.
69. Robinson SM, Jameson KA, Batelaan SF et al. Diet and its relationship with grip strength in community-dwelling older men and women: Hertfordshire cohort study. J Am Geriatr Soc 2008;56:84-90.
70. McCarthy D, Berg A. Weight Loss Strategies and the Risk of Skeletal Muscle Mass Loss. Nutrients 2021 Jul 20;13(7):2473. DOI: 10.3390/nu13072473
71. Cruz-Jentoft AJ, Bahat G, Bauer J et al.; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48(1):16-31. DOI: 10.1093/ageing/afy169
72. Xu Y, Hu T, Shen Y et al. Contribution of low skeletal muscle mass in predicting cardiovascular events: A prospective cohort study. Eur J Intern Med 2023 Aug;114:113-9. DOI: 10.1016/j.ejim.2023.05.007
73. Nguyen A, Lee P, Rodriguez EK et al. Addressing the growing burden of musculoskeletal diseases in the ageing US population: challenges and innovations. Lancet Healthy Longev 2025 May;6(5):100707. DOI: 10.1016/j.lanhl.2025.100707
74. Prado CM, Phillips SM, Gonzalez MC, Heymsfield SB. Muscle matters: the effects of medically induced weight loss on skeletal muscle. Lancet Diabetes Endocrinol 2024 Nov;12(11):785-7. DOI: 10.1016/S2213-8587(24)00272-9
75. Zhou N, Scoubeau C, Forton K et al. Lean Mass Loss and Altered Muscular Aerobic Capacity after Bariatric Surgery. Obes Facts 2022;15(2):248-56. DOI: 10.1159/000521242
76. Romeijn MM, Holthuijsen DDB, Kolen AM et al. The effect of additional protein on lean body mass preservation in post-bariatric surgery patients: a systematic review. Nutr J 2021 Mar 14;20(1):27. DOI: 10.1186/s12937-021-00688-3
77. Листок-вкладыш – информация для пациента. ТирзеттаÆ, номер регистрационного удостоверения ЛП-№(008551)-(РГ-RU).
Package leaflet – information for the patient. TirzettaÆ, registration certificate number LP-No. (008551)-(RG-RU) (in Russian).
78. Afzali AM, Muntefering T, Wiendl H et al. Skeletal muscle cells actively shape (auto)immune responses. Autoimmun Rev 2018;17:518-29.
79. Allison DB, Zhu SK, Plankey M et al. Differential associations of body mass index and adiposity with all-cause mortality among men in NHANES I and II. Int J Obes 2002;26:410-6. DOI: 10.1038/sj.ijo.0801925
80. Amirouche AC, Durieux AC, Banzet S et al. Down-regulation of Akt/mTOR signaling in response to myostatin overexpression in skeletal muscle. Endocrinology 2009;150:286-94.
81. Baht GS, Bareja A, Lee DE et al. Meteorin-like facilitates skeletal muscle repair through a Stat3/IGF-1 mechanism. Nat Metab 2020;2:278-89.
82. Batsis JA, Mackenzie TA, Emeny RT et al. Low lean mass with and without obesity and mortality: NHANES 1999–2004. J Gerontol A Biol Sci Med Sci 2017;72(10):1445-51. DOI: 10.1093/gerona/glx002
83. Beaudart C, Buckinx F, Rabenda V et al. Effects of vitamin D on muscle: systematic review and meta-analysis. J Clin Endocrinol Metab 2014;99:4336-45.
84. Bilski J, Pierzchalski P, Szczepanik M et al. Multifactorial mechanism of sarcopenia and sarcopenic obesity: role of exercise, microbiota and myokines. Cells 2022;11(1):160. DOI: 10.3390/cells11010160
85. Bonnefoy M, Gilbert T. Body composition and comorbidity in the elderly. Geriatr Psychol Neuropsychiatr Vieil 2015;13(1):29-36. DOI: 10.1684/pnv.2015.0528
86. Bosello O, Vanzo A. Obesity paradox and aging. Eat Weight Disord 2021;26:27-35.
87. Bucci L, Yani SL, Fabbri C et al. Adipokines and IGF-1 associated with skeletal muscle strength in healthy subjects. Biogerontology 2013;14:261-72.
88. Campbell C, McMillan HJ, Mah JK et al. ACE-031 in Duchenne muscular dystrophy: randomized trial. Muscle Nerve 2017;55:458-64.
89. Ceglia L, Niramitmahapanya S, da Silva Morais M et al. Vitamin D3 and skeletal muscle morphology in older women: randomized study. J Clin Endocrinol Metab 2013;98:1927-35.
90. Cleasby ME, Jamieson PM, Atherton PJ. Insulin resistance and sarcopenia: mechanistic links. J Endocrinol 2016;229:R67-R81.
91. Consitt LA, Clark BC. The vicious cycle of myostatin signaling in sarcopenic obesity. J Frailty Aging 2018;7:21-7.
92. Conway J, Duggal NA. Ageing of the gut microbiome: impact on immunosenescence and inflammageing. Ageing Res Rev 2021;68:101323.
93. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet 2019;393(10191):2636-46. DOI: 10.1016/S0140-6736(19)31138-9
94. Cuthbertson D, Smith K, Babraj J et al. Amino-acid resistance of aging muscle: anabolic signaling deficits. FASEB J 2005;19(3):422-4. DOI: 10.1096/fj.04-2640fje
95. Fiaschi T, Giannoni E, Taddei ML, Chiarugi P. Globular adiponectin activates motility and regenerative traits of muscle satellite cells. PLoS One 2012;7:e34782.
96. Gao Q, Mei F, Shang Y et al. Global prevalence of sarcopenic obesity in older adults: meta-analysis. Clin Nutr 2021;40(7):4633-41. DOI: 10.1016/j.clnu.2021.06.009
97. Ghosh S, Lertwattanarak R, de Jesus Garduno J et al. Elevated muscle TLR4 expression and metabolic endotoxemia with aging. J Gerontol A Biol Sci Med Sci 2015;70:232-46. DOI: 10.1093/gerona/glu067
98. Girgis CM, Cha KM, So B et al. Myocyte deletion of VDR causes sarcopenia and impaired muscle function in mice. J Cachexia Sarcopenia Muscle 2019;10:1228-40.
99. Goodpaster BH, Park SW, Harris TB et al. Loss of muscle strength, mass and quality in older adults. J Gerontol A Biol Sci Med Sci 2006;61(10):1059-64. DOI: 10.1093/gerona/61.10.1059
100. Gruberg L, Weissman NJ, Waksman R et al. The impact of obesity on outcomes after percutaneous coronary intervention: the obesity paradox? J Am Coll Cardiol 2002;39:578-84.
101. Guo A, Li K, Xiao Q. Sarcopenic obesity: myokines as potential diagnostic biomarkers and therapeutic targets? Exp Gerontol 2020;139:111022.
102. Huh JY, Dincer F, Mesfum E, Mantzoros CS. Irisin stimulates muscle growth-related genes and regulates adipocyte differentiation and metabolism in humans. Int J Obes 2014;38:1538-44.
103. Jones G, Trajanoska K, Santanasto AJ et al. Genome-wide meta-analysis of muscle weakness identifies susceptibility loci in older men and women. Nat Commun 2021;12:654.
104. Kastorini CM, Panagiotakos DB. The obesity paradox: methodological considerations and new insights. Maturitas 2012;72:220-4. DOI: 10.1016/j.maturitas.2012.04.012
105. Khoramipour K, Chamari K, Hekmatikar AA et al. Adiponectin: structure, physiological functions, role in diseases, and nutritional effects. Nutrients 2021;13:1180.
106. Kuswanto W, Burzyn D, Panduro M et al. Poor repair of skeletal muscle in aging mice reflects IL-33-dependent Treg accumulation defect. Immunity 2016;44:355-67.
107. Kwon JH, Moon KM, Min KW. Exercise-induced myokines explain importance of physical activity in the elderly: overview. Healthcare 2020;8:378.
108. Lana A, Valdés-Bécares A, Buño A et al. Serum leptin concentration and incident frailty in older adults. Aging Dis 2017;8:240-9.
109. Le Couteur DG, Handelsman DJ, Stanaway F et al. Sarcopenic obesity and amino acids: Concord Health and Ageing in Men Project. J Gerontol 2021;6:1000-4. DOI: 10.1093/gerona/glab076
110. Lee DC, Shook RP, Drenowatz C, Blair SN. Physical activity and sarcopenic obesity: definition, assessment, prevalence and mechanism. Future Sci OA 2016;2(3):127. DOI: 10.4155/fsoa-2016-0028
111. Lee MW, Lee M, Oh KJ. Adipose tissue-derived signatures for obesity and type 2 diabetes: adipokines, batokines and microRNAs. J Clin Med 2019;8:854.
112. Lee YH, Pratley RE. The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diabetes Rep 2005;5:70-5. DOI: 10.1007/s11892-005-0071-7
113. Markofski MM, Dickinson JM, Drummond MJ et al. Effect of age on basal muscle protein synthesis and mTORC1 signaling in men and women. Exp Gerontol 2015;65:1-7. DOI: 10.1016/j.exger.2015.02.015
114. Nakae Y, Hirasaka K, Goto J et al. Epigallocatechin-3-gallate limits muscular dystrophy in mdx mice. Histochem Cell Biol 2008;129:489-501.
115. Pei YF, Liu YZ, Yang XL, et al. Genetic architecture of appendicular lean mass: UK Biobank analysis. Commun Biol 2020;3:608.
116. Perna S, Spadaccini D, Nichetti M et alM. Osteosarcopenic visceral and subcutaneous obesity: prevalence and metabolic profile. J Aging Res 2018;11:1-8.
117. Petersson SJ, Christensen LL, Kristensen JM et al. Effect of testosterone on mitochondrial oxidative phosphorylation and lipid metabolism in aging men. Eur J Endocrinol 2014;171(1):77-88. DOI: 10.1530/EJE-14-0006
118. Poggiogalle E, Lubrano C, Gnessi L et al. Fatty Liver Index associates with relative sarcopenia and GH/IGF-1 status in obese subjects. PLoS One 2016;11:e0145811.
119. Poggiogalle E, Parrinello E, Barazzoni R et al. Therapeutic strategies for sarcopenic obesity: a systematic review. Curr Opin Clin Nutr Metab Care 2021;24(1):33-41. DOI: 10.1097/MCO.0000000000000714
120. Reidy PT, McKenzie AI, Mahmassani ZS et al. Aging impairs skeletal muscle macrophage polarization and abundance during recovery from disuse. Am J Physiol Endocrinol Metab 2019;317:E85-E98.
121. Romero-Corral A, Montori VM, Somers VK et al. Association of bodyweight with total mortality and cardiovascular events: systematic review of cohort studies. Lancet 2006;368:666-78. DOI: 10.1016/S0140-6736(06)69251-9
122. Saini J, McPhee JS, Al-Dabbagh S et al. Regenerative function of immune system: modulation of muscle stem cells. Ageing Res Rev 2016;27:67-76.
123. Semenova EA, Pranckevièienë E, Bondareva EA et al. Genomic predictors of sarcopenia and sarcopenic obesity: UK Biobank data. Nutrients 2023;15(3):758. DOI: 10.3390/nu15030758
124. Shimabukuro M. Leptin resistance and lipolysis of white adipose tissue: implications for ectopic fat deposition. J Atheroscler Thromb 2017;24:1088-9.
125. Silva TLD, Mulder A. Sarcopenia and poor muscle quality associated with severe obesity in adults. Clin Nutr ESPEN 2021;45:299-305. DOI: 10.1016/j.clnesp.2021.07.031
126. Sinha-Hikim I, Cornford M, Gaytan H et al. Testosterone supplementation and satellite cells in older men. J Clin Endocrinol Metab 2006;91(8):3024-33. DOI: 10.1210/jc.2006-0357
127. Smith GI, Villareal DT, Sinacore DR et al. Muscle protein synthesis response to exercise in obese older adults. Med Sci Sports Exerc 2012;44(7):1259-66. DOI: 10.1249/MSS.0b013e3182496a41
128. Tabata S, Aizawa M, Kinoshita M et al. The influence of isoflavone on denervation-induced muscle atrophy. Eur J Nutr 2018;58:291-300.
129. Tay L, Ding YY, Leung BP et al. Sex-specific differences in risk factors for sarcopenia in older adults. Age (Dordr) 2015;37:121.
130. Thevaranjan N, Puchta A, Schulz C et al. Age-associated microbial dysbiosis promotes intestinal permeability, inflammation, and macrophage dysfunction. Cell Host Microbe 2018;23:570-85.
131. Timmins IR, Zaccardi F, Nelson CP et al. Genome-wide association study of self-reported walking pace and health outcomes. Commun Biol 2020;3:634.
132. Tomlinson PB, Joseph C, Angioi M. Effects of vitamin D supplementation on muscle strength: systematic review and meta-analysis. J Sci Med Sport 2015;18:575-80.
133. Tovo CV, Fernandes SA, Buss C, De Mattos AA. Sarcopenia and non-alcoholic fatty liver disease: systematic review. World J Hepatol 2017;9:326-32. DOI: 10.4254/wjh.v9.i6.326
134. Tripathi D, Kant S, Pandey S, Ehtesham NZ. Resistin in metabolism, inflammation, and disease. FEBS J 2020;287:3141-9.
135. Uchitomi R, Oyabu M, Kamei Y. Vitamin D and sarcopenia: potential of vitamin D supplementation in prevention and treatment. Nutrients 2020;12(10):3189. DOI: 10.3390/nu12103189
136. Van Hollebeke RB, Cushman M, Schlueter EF, Allison MA. Abdominal muscle density inversely related to adiposity inflammatory mediators. Med Sci Sports Exerc 2018;50:1495-503.
137. Vella CA, Cushman M, Van Hollebeke RB, Allison MA. Abdominal muscle area and radiodensity associated with adiponectin and leptin. Obesity 2018;26:1234-41.
138. Willems SM, Wright DJ, Day FR et al. Large-scale GWAS identifies loci for hand grip strength and muscular fitness. Nat Commun 2017;8:16015.
139. Yang ZY, Chen WL. Association between serum leptin and sarcopenic obesity. J Inflamm Res 2021;14:3481-7.
140. Yarasheski K, Bhasin S, Sinha-Hikim I et al. Serum myostatin-immunoreactive protein increased in elderly with muscle wasting. J Nutr Health Aging 2002;6(5):343-8.
141. Zempo H, Miyamoto-Mikami E, Kikuchi N et al. Heritability estimates of muscle strength phenotypes: systematic review and meta-analysis. Scand J Med Sci Sports 2017;27:1537-46.
142. Zhou Q, Du J, Hu Z et al. Evidence for adipose-muscle crosstalk: opposing regulation of muscle proteolysis by adiponectin and fatty acids. Endocrinology 2007;148:5696-705.
143. Zhu YQ, Peng N, Zhou M et al. Tai Chi and whole-body vibration therapy in sarcopenic men: randomized controlled trial. Eur J Ageing 2019;16:273-82.
Для цитирования:Дзгоева Ф.Х., Демидова В.В. Саркопеническое ожирение у мужчин: от этиопатогенеза к терапевтическим стратегиям в лечении. Клинический разбор в общей медицине. 2025; 6 (10): 7–16. DOI: 10.47407/kr2025.6.10.00687
Журнал предоставляет свободный доступ с возможностью использовать статьи в некоммерческих целях при условии указания авторства в рамках лицензии CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/deed.ru)
